Abstract:
:Several studies have found a correlation between the presence of circulating maternal autoantibodies and neuronal dysfunction in the neonate. Specifically, maternal anti-brain autoantibodies, which may access the fetal compartment during gestation, have been identified as one risk factor for developing autism spectrum disorder (ASD). Studies by our laboratory elucidated seven neurodevelopmental proteins recognized by maternal autoantibodies whose presence is associated with a diagnosis of maternal autoantibody-related (MAR) autism in the child. While the specific process of anti-brain autoantibody generation is unclear and the detailed pathogenic mechanisms are currently unknown, identification of the maternal autoantibody targets increases the therapeutic possibilities. The potential therapies discussed in this review provide a framework for possible future medical interventions.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Fox-Edmiston E,Van de Water Jdoi
10.1007/s40263-015-0279-2subject
Has Abstractpub_date
2015-09-01 00:00:00pages
715-24issue
9eissn
1172-7047issn
1179-1934pii
10.1007/s40263-015-0279-2journal_volume
29pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract::There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200620010-00001
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:There is growing epidemiological evidence that opioids may increase the risk of unintentional injuries and it is plausible that the time of initiation is most critical in that respect. Studies on fall-related injuries remain few, limited and mostly focused on specific groups of elderly patients. OBJECTIVE:T...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-013-0038-1
更新日期:2013-02-01 00:00:00
abstract::New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418140-00005
更新日期:2004-01-01 00:00:00
abstract::NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...
journal_title:CNS drugs
pub_type: 已发布勘误
doi:10.1007/s40263-018-0595-4
更新日期:2019-01-01 00:00:00
abstract:BACKGROUND:Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine. OBJECTIVE:The objective of this study was to assess the liver safety and identify the characteristics of patients who developed a significant increase i...
journal_title:CNS drugs
pub_type: 杂志文章,meta分析
doi:10.1007/s40263-016-0351-6
更新日期:2016-09-01 00:00:00
abstract::The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by mutations in at least 13 different genes and primarily affect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epi...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-019-00620-8
更新日期:2019-04-01 00:00:00
abstract::Cognitive dysfunction is a major cause of disability in patients with multiple sclerosis (MS). The prevalence of cognitive dysfunction is estimated at 45 to 65%. Natural history studies suggest that once cognitive dysfunction develops in a patient with MS, it is not likely to remit. Unlike physical disability in MS, c...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200216070-00002
更新日期:2002-01-01 00:00:00
abstract:BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...
journal_title:CNS drugs
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1007/s40263-018-0586-5
更新日期:2019-01-01 00:00:00
abstract::For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressa...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418080-00003
更新日期:2004-01-01 00:00:00
abstract::Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-016-0337-4
更新日期:2016-05-01 00:00:00
abstract::An explosion in antiepileptic drug (AED) therapy began in the 1990s with the licensing of 9 new chemical entities and more to come. Important differences between AEDs may not be detected by regulatory trials, which are designed to satisfy licensing requirements and often diverge considerably from everyday clinical pra...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115010-00001
更新日期:2001-01-01 00:00:00
abstract:OBJECTIVE:This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. METHODS:Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/da...
journal_title:CNS drugs
pub_type: 杂志文章,随机对照试验
doi:10.1007/s40263-014-0165-3
更新日期:2014-07-01 00:00:00
abstract::Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0123-5
更新日期:2013-12-01 00:00:00
abstract::Mitoxantrone (Novantrone), a synthetic anthracenedione derivative, is an antineoplastic, immunomodulatory agent. Its presumed mechanism of action in patients with multiple sclerosis (MS) is via immunomodulatory mechanisms, although these remain to be fully elucidated. Intravenous mitoxantrone treatment improved neurol...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418060-00010
更新日期:2004-01-01 00:00:00
abstract::This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115090-00005
更新日期:2001-01-01 00:00:00
abstract::Tramadol-an atypical opioid analgesic-has a unique pharmacokinetic and pharmacodynamic profile, with opioidergic, noradrenergic, and serotonergic actions. Tramadol has long been used as a well-tolerated alternative to other drugs in moderate pain because of its opioidergic and monoaminergic activities. However, cumula...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-019-00623-5
更新日期:2019-05-01 00:00:00
abstract::Alzheimer's disease affects nearly 5 million Americans currently and, as a result of the baby boomer cohort, is predicted to affect 14 million Americans and 22 million persons totally worldwide in just a few decades. Alzheimer's disease is present in nearly half of individuals aged 85 years. The main symptom of Alzhei...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200317090-00004
更新日期:2003-01-01 00:00:00
abstract::Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00766-w
更新日期:2020-11-01 00:00:00
abstract:BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-013-0102-x
更新日期:2013-11-01 00:00:00
abstract::Down syndrome (DS), which results from an extra copy of chromosome 21 (trisomy 21), is the most common genetically defined cause of intellectual disability. Although no pharmacotherapy aimed at counteracting the cognitive and adaptive deficits associated with this genetic disorder has been approved at present, there h...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0089-3
更新日期:2013-09-01 00:00:00
abstract::The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200620080-00004
更新日期:2006-01-01 00:00:00
abstract:OBJECTIVE:To determine the efficacy and tolerability of zolmitriptan 2.5 mg oral tablet as an acute treatment for menstrual migraine attacks. METHODS:This was a two-phase, multicentre, randomised, double-blind, placebo-controlled, parallel-group outpatient study (Phase I is reported here). The study was conducted at 2...
journal_title:CNS drugs
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2165/00023210-200620120-00005
更新日期:2006-01-01 00:00:00
abstract:OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11590450-000000000-00000
更新日期:2011-06-01 00:00:00
abstract::Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-014-0162-6
更新日期:2014-06-01 00:00:00
abstract::Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11633910-000000000-00000
更新日期:2012-09-01 00:00:00
abstract:BACKGROUND AND OBJECTIVE:Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-level data were used t...
journal_title:CNS drugs
pub_type: 杂志文章,随机对照试验
doi:10.1007/s40263-017-0462-8
更新日期:2017-10-01 00:00:00
abstract:BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00708-6
更新日期:2020-03-01 00:00:00
abstract::Electroconvulsive therapy (ECT) is used in the treatment of severe psychiatric disorders. It involves the induction of a seizure for therapeutic purposes by the administration of a variable-frequency electrical stimulus via electrodes applied to the scalp. The original application of ECT in non-anaesthetised patients ...
journal_title:CNS drugs
pub_type: 指南,杂志文章,实务指引,评审
doi:10.2165/00023210-200519090-00002
更新日期:2005-01-01 00:00:00
abstract::Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel alpha(2)-delta proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmit...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200519030-00007
更新日期:2005-01-01 00:00:00
abstract::Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0041-6
更新日期:2013-03-01 00:00:00